Conference Day Two

Thursday June 20, 2024

8:00 am Morning Coffee & Light Breakfast

8:50 am Chair’s Opening Remarks

  • Mao Taketani Director, Synthetic Biology, Jorna Therapeutics

Highlighting Strategies for Optimizing RNA Editing Therapeutics to Effectively Treat a Wide Landscape of Genetic Diseases

9:00 am Unlocking the Edit-Verse: Combining Machine Learning & Multiple AIMer Applications to Build a High-Impact RNA Editing Pipeline

  • Kenneth Longo Vice President - Discovery Data Science, Wave Life Sciences
  • Ginnie Yang Senior Vice President, Translational Medicine, Wave Life Sciences

Synopsis

  • Leveraging deep learning models and genetic datasets to identify new RNA editing targets and edit sites
  • New opportunities in correction and mRNA upregulation in hepatic and non-hepatic diseases

9:30 am Wobble Base Pairs Enable Site-Directed RNA Base Editing with High Efficiency & Precision in-vivo

Synopsis

  • GU wobble base pairs in the context of RNA editing
  • In-silico optimized guide RNA design
  • Limiting factors for RNA base editing in the murine CNS

10:00 am Morning Break & Networking

Addressing Challenges of Durability to Achieve More Effective Therapeutics for Treating Rare Diseases

11:00 am Roundtable Discussion: Discussing Strategies for Improved Longevity of Editing Therapeutics to Achieve More Durable Effects

  • Venkat Krishnamurthy Senior Vice President & Head Of Platform & Ribonucleic Acid Editing, Korro Bio

Synopsis

  • How can the delivery platform used enhance the durability of the RNA editing machinery?
  • Is it possible to incorporate self-replicating RNA for continued editing to increase longevity?
  • What strategies is the community currently trying to improve durability? Is it possible to incorporate the RNA editing system into the genome?

12:00 pm Lunch & Networking

Uncovering Brand-New Data Updates for Progression Towards the Clinic & Accelerating Development of RNA Editors

1:00 pm RestorAATion: First Clinical Progam Evaluating an RNA Editing Therapeutics in Humans

Synopsis

  • Preclinical data supporting WVE-006 as a best-in-class approach for AATD
  • Overview of RestorAATion study program

1:30 pm Edit the Message: Rewrite the Future

  • Venkat Krishnamurthy Senior Vice President & Head Of Platform & Ribonucleic Acid Editing, Korro Bio

Synopsis

  • At Korro Bio, we are developing our proprietary OPERA platform (Oligonucleotide Promoted Editing of RNA), which utilizes synthetic oligonucleotides that recruit adenosine deaminases acting on RNA (ADARs) to repair disease-causing mutations at the RNA level
  • In addition to repairing standard G-to-A mutations, our platform enables the modulation of protein function by changing the amino acid code
  • This presentation will provide an update on our OPERA platform and our progress towards the clinic

2:00 pm Developing Axiomer RNA Editing Technology Towards Clinical Development

Synopsis

  • Increasing knowledge of ADAR biology, selecting models for prediction of Axiomer potential in human tissue, and ensuring EON sequence and delivery optimization
  • Reviewing the potential of Axiomer platform editing capabilities in vivo and assessing functional effect in therapeutic targets
  • Developing Axiomer RNA editing platform in preparation for clinical development and supporting discovery of new therapeutic applications

2:30 pm Afternoon Break & Networking

Identifying New Applications of RNA Editing to Unleash its Full Potential for Accelerated Treatment of More Widespread Disease

3:30 pm RADAR: An ADAR-Based Technology for Selective Translation of Therapeutic Proteins

Synopsis

  • RADAR enables cell-type specific RNA expression by sensing intracellular RNA markers that define the cell type, disease state or cell state of interest to activate translation of a synthetic transcript
  • We are inspired by ADAR biology to promote efficient editing of exogenous mRNA substrates in a marker-dependent manner
  • RADAR enables precise, autonomous cell-selectivity that can bring specificity to broadly-targeting delivery vectors for DNA and mRNA

4:00 pm Engineering gRNA-Free Single Enzymes for Programmable RNA Base Editing RNA

  • Eerik Kaseniit, PhD Chief Scientific Officer & Co-Founder, Radar Therapeutics
  • Zeneng Wang Chair Professor, School of Life Sciences, Southern University of Science and Technology, Shenzhen

Synopsis

  • We developed a new system by combining programmable RNA binding domains with different RNA deaminase domains (i.e., functional module), achieving specific and efficient RNA base editing for both A-to-G and C-to-U conversion. All these editing enzymes are originated from human proteins, suggesting a low immunity compared to the CRISPR-based editing systems that contain bacterial proteins
  • The RNA deaminase domains (APOBECs) were further modified to optimize the specificity and efficiency of base editing, achieving effective C-to-U editing in all sequence contexts
  • This system showed high efficiency to correct disease-causing mutations in animal model, especially show phenotypic reversion in a mouse model of autism

4:30 pm miRNA-Based Logic Circuits Encoded on Self-Amplifying RNA for Highly Specific Cancer Cell Classification

  • Ron Weiss Professor, Massachusetts Institute of Technology

Synopsis

  • Therapeutic agents encoded on self-amplifying RNA and delivered in LNPs to cells perform multi-input RNA-based logic circuit functions
  • Expression of therapeutic proteins and amplification of the RNA within any given cell is determined by the RNA circuit based on the presence or absence of several RNA biomarkers
  • Multiple RNA inputs affect the state and stability of the RNA molecule encoding the therapeutic programs

5:00 pm Chair’s Closing Remarks & End of 5th RNA Editing Summit 2024

  • Mao Taketani Director, Synthetic Biology, Jorna Therapeutics